Shattuck Labs shares are trading higher after the company announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs' stock price has increased following the announcement of positive initial topline dose-expansion data from its Phase 1A/B clinical trial of SL-172154, used in combination with AZA to treat HR-MDS and TP53m AML patients.
December 13, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shattuck Labs' stock price is experiencing an upswing due to the release of favorable initial data from its clinical trial involving SL-172154, which could potentially lead to increased investor confidence in the company's pipeline.
The positive clinical trial results are a significant milestone for Shattuck Labs, likely leading to increased investor interest and a higher stock price in the short term. The data suggests potential for the drug's efficacy and safety, which are critical factors in the drug's development and commercial success.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100